Back to Search
Start Over
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
- Source :
-
Blood advances [Blood Adv] 2021 Feb 09; Vol. 5 (3), pp. 861-871. - Publication Year :
- 2021
-
Abstract
- The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified in late 2019 as the causative agent of COVID-19, was declared a pandemic by the World Health Organization on 11 March 2020. Widespread community transmission in the United States triggered a nationwide shutdown, raising major challenges for administration of hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR)-T cell therapies, leading many centers to delay or cancel operations. We sought to assess the impact of the COVID-19 pandemic on operations and clinical outcomes for HSCT and CAR-T cellular therapies at the Dana-Farber Cancer Institute by reviewing administration and outcomes in 127 cell therapy patients treated during the initial COVID-19 surge: 62 adult allogeneic HSCT (allo-HSCT), 38 autologous HSCT (auto-HSCT), and 27 CAR-T patients. Outcomes were compared with 66 allo-HSCT, 43 auto-HSCT, and 33 CAR-T patients treated prior to the pandemic. A second control cohort was evaluated for HSCT groups to reflect seasonal variation in infections. Although there were changes in donor selection and screening as well as cryopreservation patterns of donor products, no differences were observed across groups in 100-day overall survival, progression-free survival, rates of non-COVID-19 infections, including hospital length of stay, neutrophil engraftment, graft failure, acute graft-versus-host disease in allo-HSCT patients, or cytokine release syndrome and neurotoxicity in CAR-T patients. No HSCT patients contracted COVID-19 between days 0 and 100. One CAR-T patient contracted COVID-19 at day +51 and died of the disease. Altogether, our data indicate that cellular therapies can be safely administered throughout the ongoing COVID-19 pandemic with appropriate safeguards.<br /> (© 2021 by The American Society of Hematology.)
- Subjects :
- Adult
Aged
COVID-19 mortality
COVID-19 pathology
COVID-19 virology
Female
Graft vs Host Disease etiology
Humans
Immunotherapy, Adoptive
Kaplan-Meier Estimate
Male
Middle Aged
Progression-Free Survival
SARS-CoV-2 isolation & purification
Transplantation, Autologous
Transplantation, Homologous
United States
Young Adult
COVID-19 therapy
Hematopoietic Stem Cell Transplantation adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 2473-9537
- Volume :
- 5
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Blood advances
- Publication Type :
- Academic Journal
- Accession number :
- 33560397
- Full Text :
- https://doi.org/10.1182/bloodadvances.2020003883